BACK

Alan Selby

Alan Selby

Executive Director

London Office  |  alan.selby@torreya.com   |   +44 (0) 207 451 4553

Alan Selby, an Executive Director at Torreya, works on strategic transactions and financings in addition to overseeing Torreya’s junior staff in London.

Before joining Torreya’s team in 2011, he was an Investment Manager at LGV, a UK-based middle-market private equity fund, focusing on healthcare investments. Alan also served as an advisor to the healthcare team at Booz & Company and at Macquarie Group from 2006 to 2009 where he worked on deals in healthcare, infrastructure, and structured finance.

Prior to his career in Finance, Alan was a practicing doctor in teaching hospitals in London specializing in neurology, infectious diseases, endocrinology, and elderly care.

Alan holds both an M.Sc. in finance from INSEAD and an M.B.Ch.B. with Hons., University of Liverpool, UK.

Selected Transactions

Opiant Pharmaceuticals
Sale of royalties to
SWK Holdings
$17.5 million
December 2016
Apollo Endosurgery
Merger with
Lpath
$251 million
December 2016
DBV Technologies
License of
milk allergy product to
Nestle
€100 million
May 2016
arGEN-X
License of preclinical
derm antibody to
LEO Pharma
Up to €105 million
May 2015
Inviragen
Sale of
vaccine company to
Takeda
$250 million with
$35 million upfront
May 2013
Lysogene
Licensing of ex European rights for LYS-SAF302 to
Sarepta Therapeutics
Up to $125 Millionwith committed payments of $29m plus royalties
October 2018
Ipsen
Acquisition of
OctreoPharm Sciences
Up to €50 million
May 2015
Lightlake Therapeutics
License of naloxone
opioid overdose reversal treatment to
Adapt Pharma
$55+ million
December 2014
Aseptix Health Sciences
License of antimicrobial technology to
Ecolab
Undisclosed
December 2014
DBV Technologies
Global offering advisory
Undisclosed
$133 million
October 2014
4-Antibody AG
Sale to
Agenus
$40+ million with
$10 million upfront
January 2014
Almac
License of chemotherapy benefit test for high risk breast cancer to
Genomic Health
$9 million + milestones and royalties
November 2013
DBV Technologies
Financial advisor in
private placement
Undisclosed
€29.9 million
November 2013
Selexis
Sale of basket of
royalties to
Ligand
$6 million upfront
April 2013
SpePharm
Collaboration with
Norgine
Undisclosed
December 2012